gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 01 Mar 2015.

V-raf murine sarcoma viral oncogene homolog B1

BRAF
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: KRAS, CAN, Raf, HAD, EGFR
Papers using BRAF antibodies
Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF
Supplier
Pal Soumitro, In PLoS ONE, 2009
... All primary antibodies were purchased from Cell Signaling Technology except the following: anti-BRAF from Santa Cruz Biotechnology, anti-CRAF from BD Biosciences, ...
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults
Supplier
LiVolsi Virginia A et al., In CytoJournal, 2000
... The amplified products were electrophoresed on a 1.2% gel at 110 V for 1.5 hours and the BRAF bands (~220 bp) were cut using sterile blade and purified using Qiagen Gel Extraction Kit (Hilden, ...
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
Supplier
Brinker Achim et al., In Current Chemical Genomics, 1993
... Unconjugated B-Raf antibody was from Santa Cruz Biotechnology (sc-5284), pMEK1/2 antibody from ...
Papers on BRAF
Dabrafenib in the treatment of metastatic or unresectable melanoma.
New
Hogg et al., Toronto, Canada. In Expert Rev Anticancer Ther, 31 Mar 2015
Dabrafenib is a potent inhibitor of mutant BRAF.
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies.
New
Impact
Bivona et al., San Francisco, United States. In Nat Genet, 31 Mar 2015
RAF and MEK inhibitors are initially but only transiently effective in some but not all patients with BRAF gene mutation and are largely ineffective in those with RAS gene mutation because of resistance.
Differential allelic expression of SOS1 and hyperexpression of the activating SOS1 c.755C variant in a Noonan syndrome family.
New
Riva et al., Milano, Italy. In Eur J Hum Genet, 25 Mar 2015
After a mutation screening of the known NS genes PTPN11, SOS1, RAF1, KRAS, GRB2, BRAF and SHOC2 we found the heterozygous c.755T>C variant in SOS1 causing the p.I252T amino-acid substitution, which was considered possibly pathogenetic by bioinformatic predictions.
AKT1 E17K in Colorectal Carcinoma is Associated with BRAF V600E but not MSI-H status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
New
Arcila et al., Kettering, United Kingdom. In Mol Cancer Res, 24 Mar 2015
Interestingly, in comparison to PIK3CA mutants, AKT1 E17K was significantly associated with mucinous morphology and concurrent BRAF V600E mutation.
PDK1 and SGK3 contribute to the growth of BRAF mutant melanomas and are potential therapeutic targets.
New
Ronai et al., Sanford, United States. In Cancer Res, 24 Mar 2015
UNASSIGNED: Melanoma development involves members of the AGC kinase family including AKT, PKC and, most recently, PDK1, as elucidated recently in studies of Braf::Pten mutant melanomas.
Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial.
New
Impact
Giaccone et al., Bethesda, United States. In J Clin Oncol, 09 Mar 2015
Patients were enrolled onto a not-otherwise-specified arm and treated with standard-of-care therapies or one of the following five biomarker-matched treatment groups: erlotinib for EGFR mutations; selumetinib for KRAS, NRAS, HRAS, or BRAF mutations; MK2206 for PIK3CA, AKT, or PTEN mutations; lapatinib for ERBB2 mutations or amplifications; and sunitinib for KIT or PDGFRA mutations or amplification.
Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction.
New
Impact
Lo et al., Los Angeles, United States. In Cancer Cell, 09 Mar 2015
Combined BRAF- and MEK-targeted therapy improves upon BRAF inhibitor (BRAFi) therapy but is still beset by acquired resistance.
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis.
Review
New
Barni et al., Milano, Italy. In Eur J Cancer, 09 Mar 2015
We examined the impact of C and P on progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) in advanced colorectal cancer (CRC) patients who have RAS-wt/BRAF-mutant (BRAF-mut) status.
mTOR Signaling in Melanoma: Oncogene-Induced Pseudo-Senescence?
New
Impact
Sharpless et al., Chapel Hill, United States. In Cancer Cell, 12 Feb 2015
In this issue of Cancer Cell, Damsky and colleagues suggest activation of mTORC1 and mTORC2 is required for OIS evasion in human melanomas harboring oncogenic BRAF mutations.
mTORC1 Activation Blocks Braf(V600E)-Induced Growth Arrest but Is Insufficient for Melanoma Formation.
New
Impact
Bosenberg et al., New Haven, United States. In Cancer Cell, 12 Feb 2015
Braf(V600E) induces benign, growth-arrested melanocytic nevus development, but also drives melanoma formation.
Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer.
Review
New
Furukawa, Tokyo, Japan. In Front Oncol, Dec 2014
Mutations of KRAS or BRAF and epigenetic abrogation of DUSP6 contribute synergistically to the constitutive activation of MAPK.
Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer.
Review
New
Dhillon et al., Melbourne, Australia. In Front Oncol, Dec 2014
Such plasticity is thought to arise through interactions between aberrant signaling events, including persistent activation of the APC/╬▓-catenin and KRAS/BRAF/ERK pathways, and the tumor microenvironment.
Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.
Review
New
Barrio et al., Buenos Aires, Argentina. In Front Immunol, Dec 2014
However, the discovery of prevalent BRAF mutations in at least 50% of melanoma tumors led to development of BRAF-inhibitors, and other drugs targeting the MAPK pathway including MEK-inhibitors, are changing this reality.
The Role of BPTF in Melanoma Progression and in Response to BRAF-Targeted Therapy.
New
Kashani-Sabet et al., San Francisco, United States. In J Natl Cancer Inst, Dec 2014
The functional role of BPTF in melanoma progression was investigated using assays of colony formation, invasion, cell cycle, sensitivity to selective BRAF inhibitors, and in xenograft models of melanoma progression (n = 12 mice per group).
[Targeted therapies in non-small cell lung cancer in 2014.]
Review
New
Besse et al., Strasbourg, France. In Rev Mal Respir, Dec 2014
Personalized medicine is now a reality for patients with advanced NSCLC on the basis of routine screening for EGFR, HER2, KRAS, BRAF, PI3KCA mutations and EML4-ALK rearrangement.
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
GeneRIF
Pritchard et al., Leicester, United Kingdom. In Genes Dev, 2012
endogenous expression of (L597V)Braf leads to approximately twofold elevated Braf kinase activity and weak activation of the Mek/Erk pathway
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.
GeneRIF
Eberhart et al., Baltimore, United States. In J Neuropathol Exp Neurol, 2012
The results of this study supported an important role for BRAF duplication and MAPK pathway activation in gliomas of the optic nerve proper.
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Review
GeneRIF
Xing et al., Baltimore, United States. In Medicine (baltimore), 2012
Thus, in this meta-analysis, the BRAF mutation in PTC was significantly associated with PTC recurrence, lymph node metastasis, extrathyroidal extension, and advanced stage AJCC III/IV.
KRAS and BRAF mutations in Serbian patients with colorectal cancer.
GeneRIF
Jankovic et al., Belgrade, Serbia. In J Buon, 2012
the spectrum and frequency distribution of the identified KRAS and BRAF mutations in Serbian patient with colorectal cancer are in good accordance with literature data.
A cardio-facio-cutaneous syndrome case with tight Achilles tendons.
GeneRIF
Ozkinay et al., ─░zmir, Turkey. In Genet Couns, 2011
Cardio-facio-cutaneous syndrome is caused by heterogeneous mutations in BRAF gene.
share on facebooktweetadd +1mail to friends